6 November 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

Scrip Code: 543064

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Outcome of the Meeting of the Board of Directors

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of the Company ("Board") at its meeting held today, i.e., 6 November 2026, has, *inter alia*, approved the following:

1. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30 September 2026 pursuant to Regulation 33 of the SEBI Listing Regulations. In this connection, we enclose herewith the following documents as Annexure - I:

   a) Unaudited Standalone and Consolidated Financial Results along with Statement of Assets and Liabilities and Cash Flow Statements;
   b) Limited Review Reports from the Statutory Auditors on the above financial results;
   c) Press Release on the financial results; and
   d) Investor Presentation.

2. Appointment of Dr. Kuber Jagdale (DIN: 12037580) as an Additional Director, designated as Chief Technical Officer & Executive Director, based on the recommendation of the Nomination and Remuneration Committee, for a period of 5 (five) years effective from 7 November 2026 till 6 November 2031, liable to retire by rotation, subject to the approval of the shareholders of the Company and such other approvals as applicable.

   Mr. Jagdale is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

3. The proposed equity investment of 26% in the SPV (under incorporation) to be engaged in solar power generation for the purpose of captive consumption of the company`s plant operation.

   The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 for item no. 2 & 3 above, are set out in Annexure – II & III respectively.

The aforesaid information is also being made available on the Company's website at www.cohance.com.

The Board Meeting commenced at 2:30 pm (IST) and concluded at 5:30 pm (IST).

We request you to take the above on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited*)*

Sisira Kumar Mishra
Digitally signed by Sisira Kumar Mishra
Date: 2026.11.06 17:46:13 +05'30'

Sisir K. Mishra
Company Secretary & Compliance Officer

Encl: as above

COHANCE LIFESCIENCES LIMITED

(formerly known as Suven Pharmaceuticals Limited)

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midco, Mumbai, Mumbai, Maharashtra, India, 400093

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

₹ In Crores

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the quarter ended			For the Half year ended		For the year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	Revenue from operations	416.69	359.89	497.79	776.58	981.37	2,030.50
	Other income	20.57	12.16	26.30	32.73	39.40	44.73
	Total income	**437.26**	**372.05**	**524.09**	**809.31**	**1,020.77**	**2,075.23**
2	**Expenses**						
	a) Cost of materials consumed	230.20	151.90	188.19	382.10	363.35	691.27
	b) Changes in inventories of finished goods and work-in-progress	(94.86)	(41.33)	(49.81)	(136.19)	(78.98)	(38.58)
	c) Employee benefits expense	117.03	96.34	95.10	213.37	198.53	380.43
	d) Finance costs	3.35	2.12	5.24	5.47	12.04	22.46
	e) Depreciation and amortisation expense	34.12	34.32	31.20	68.44	62.56	133.58
	f) Other expenses	147.68	126.49	133.45	274.17	263.41	542.97
	Total expenses	**437.52**	**369.84**	**403.37**	**807.36**	**820.91**	**1,732.13**
3	**Profit/(Loss) before exceptional items & tax (1-2)**	**(0.26)**	**2.21**	**120.72**	**1.95**	**199.86**	**343.10**
4	Exceptional items (refer note 4)	-	-	-	-	8.10	29.47
5	**Profit/(Loss) before tax (3-4)**	**(0.26)**	**2.21**	**120.72**	**1.95**	**191.76**	**313.63**
6	Tax expenses						
	a) Current tax	-	-	26.21	-	44.36	73.41
	b) Current tax - earlier years	(13.82)	-	-	(13.82)	-	4.69
	c) Deferred tax	0.29	0.80	0.22	1.09	0.54	6.82
	Total tax expense (net)	**(13.53)**	**0.80**	**26.43**	**(12.73)**	**44.90**	**84.92**
7	**Net profit for the period/year(5-6)**	**13.27**	**1.41**	**94.29**	**14.68**	**146.86**	**228.71**
8	**Other comprehensive income/ (loss)**						
8.a	Items that will not be reclassified to profit or loss						
	(i) Gain on remeasurement of defined benefit plan	0.10	0.20	(0.05)	0.30	0.06	2.05
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	(0.05)	0.01	(0.05)	(0.02)	(0.52)
8.b	Items that will be reclassified to profit or						
	(i) Effective portion of gain / (loss) on hedging instrument in a cash flow hedging	1.94	7.87	(8.64)	9.81	(8.64)	(9.93)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.51)	(1.98)	2.18	(2.49)	2.18	2.50
	Total other comprehensive income/(loss) for the period/year	**1.53**	**6.04**	**(6.50)**	**7.57**	**(6.42)**	**(5.90)**
9	**Total comprehensive income for the period/year (7+8)**	**14.80**	**7.45**	**87.79**	**22.25**	**140.44**	**222.81**
10	**Paid-up equity share capital**	**38.26**	**38.26**	**38.26**	**38.26**	**38.26**	**38.26**
	Face Value of the Share	**₹1.00**	**₹1.00**	**₹1.00**	**₹1.00**	**₹1.00**	**₹1.00**
11	Other equity						4,441.85
12	**Earning Per Share (EPS)-Face value of ₹1/- each)**						
	a) Basic	0.35	0.04	2.46	0.39	3.84	5.98
	b) Diluted	0.34	0.04	2.46	0.38	3.83	5.97
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

WALKER CHANDIOK & Co LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals Limited) ★

COHANCE LIFESCIENCES LIMITED

(formerly known as Suven Pharmaceuticals Limited)

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midco, Mumbai, Mumbai, Maharashtra, India, 400093

₹ In Crores

PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	For the quarter ended			For the Half year ended		For the year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	Revenue from operations	476.65	422.26	555.57	898.91	1,104.88	2,268.55
	Other income	12.41	12.25	15.60	24.66	29.77	34.09
	Total income	489.06	434.51	571.17	923.57	1,134.65	2,302.64
2	**Expenses**						
	a) Cost of materials consumed	236.64	158.68	191.60	395.32	369.93	705.39
	b) Changes in inventories of finished goods and work-in-progress	(97.55)	(38.40)	(50.47)	(135.95)	(80.66)	(42.76)
	c) Employee benefits expense	153.54	132.96	126.72	286.50	260.04	507.71
	d) Finance costs	8.37	6.74	8.76	15.11	18.94	37.24
	e) Depreciation and amortisation expense	50.17	49.54	44.02	99.71	89.16	187.33
	f) Other expenses	148.64	167.86	166.77	316.50	322.61	671.22
	Total expenses	499.81	477.38	487.40	977.19	980.02	2,066.13
3	**Profit/(loss) before tax and exceptional items (1-2)**	(10.75)	(42.87)	83.77	(53.62)	154.63	236.51
4	Exceptional items (refer note 4)	-	-	-	-	8.10	29.47
5	**Profit/(loss) before tax and share of associate (3-4)**	(10.75)	(42.87)	83.77	(53.62)	146.53	207.04
6	Tax expenses						
	a) Current tax	1.43	2.13	27.04	3.56	45.22	75.20
	b) Current tax - earlier years	(13.82)	0.04	-	(13.78)	-	4.69
	c) Deferred tax	(0.63)	0.15	(9.66)	(0.48)	(11.48)	(22.97)
	Total tax expense (net)	(13.02)	2.32	17.38	(10.70)	33.74	56.92
7	**Net profit/(loss) after tax before share of associate (5-6)**	2.27	(45.19)	66.39	(42.92)	112.79	150.12
8	Share of profit/(loss) of Associate (refer note 5)	-	-	-	-	-	-
9	**Net profit/(loss) for the period/year (7-8)**	2.27	(45.19)	66.39	(42.92)	112.79	150.12
10	**Net profit/(loss) for the period/year attributable to**						
	a) Shareholders of the company	15.22	(24.12)	74.08	(8.90)	122.96	179.23
	b) Non-controlling interest	(12.95)	(21.07)	(7.69)	(34.02)	(10.17)	(29.11)
11	Other comprehensive income						
11.a	Items that will not be reclassified to profit or loss						
	(i) Gain / (loss) on remeasurement of defined benefit plan	0.10	0.19	(0.05)	0.29	0.06	2.13
	(ii) Change in the fair value of equity instrument classified at FVOCI	0.00	-	-	-	-	94.65
	(iii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.05)	0.01	(0.05)	(0.02)	(26.56)
11.b	Items that will be reclassified to profit or loss						
	(i) Effective portion of gain / (loss) on hedging instrument in a cash flow hedging	1.94	7.87	3.86	9.81	3.72	(9.93)
	(ii) Exchange differences on Translating foreign operations	5.40	(0.24)	-	5.16	-	36.25
	(ii) Income tax relating to items that will be reclassified to profit or loss	(0.51)	(1.98)	2.18	(2.49)	2.18	2.50
	Total other comprehensive income for the period/year	6.93	5.79	6.00	12.72	5.94	99.04
12	**Total comprehensive income/(loss) for the period/year (9+11)**	9.20	(39.40)	72.39	(30.20)	118.73	249.16
13	**Total comprehensive income/(loss) for the period/year attributable to**						
	a) Shareholders of the company	21.16	(18.29)	77.09	2.87	125.91	270.68
	b) Non-controlling interest	(11.96)	(21.11)	(4.70)	(33.07)	(7.18)	(21.52)
14	Paid-up equity share capital	38.26	38.26	38.26	38.26	38.26	38.26
	Face value of the share	₹1.00	₹1.00	₹1.00	₹1.00	₹1.00	₹1.00
15	Other equity						3,873.03
16	**Earning Per Share (EPS)- (Face value of ₹1/- each)**						
	a) Basic	0.40	(0.63)	1.94	(0.23)	3.22	4.69
	b) Diluted	0.38	(0.65)	1.93	(0.27)	3.20	4.68
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

WALKER CHANDIOK & CO LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals Limited)

COHANCE LIFESCIENCES LIMITED

(formerly known as Suven Pharmaceuticals Limited)

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Statement of assets and liabilities

Rs. in Crores

	Particulars	Standalone as at		Consolidated as at	
		30-Sep-26	31-Mar-26	30-Sep-26	31-Mar-26
A	**ASSETS**	**Unaudited**	**Audited**	**Unaudited**	**Audited**
1	**Non-current assets**				
	(a) Property, plant and equipment	1,508.58	1,545.66	1,727.05	1,759.01
	(b) Right of use of assets	55.10	62.13	216.13	231.07
	(c) Capital work-in-progress	175.03	144.06	215.81	173.22
	(d) Goodwill	644.11	644.11	1,290.19	1,283.65
	(e) Other intangible assets	31.35	35.98	84.74	95.01
	(f) Intangible assets under development	7.14	1.74	81.38	4.51
	(g) Financial assets				
	I. Investments	1,174.44	925.26	265.91	262.23
	II.Loans	-	1.28	-	1.28
	III.Other financial assets	25.16	29.36	35.14	32.44
	(h) Non-current tax asset,(net)	7.05	37.74	9.75	39.18
	(i) Deferred tax asset,(net)	-	-	1.59	2.64
	(j) Other non-current assets	11.55	17.21	11.67	17.44
	Total non-current assets	**3,639.51**	**3,444.53**	**3,939.36**	**3,901.68**
2	**Current assets**				
	(a) Inventories	708.96	540.13	734.34	562.23
	(b) Financial assets				
	I. Investments	165.78	261.37	185.12	266.32
	II.Trade receivables	432.29	641.61	469.02	681.01
	III.Cash and cash equivalents	19.34	13.11	98.63	49.14
	IV. Bank balances other than (III) above	6.54	6.88	9.18	10.52
	V. Loans	2.11	7.97	2.18	7.97
	VI. Other financial assets	25.51	2.76	8.47	1.81
	(c) Other current assets	171.79	194.84	185.74	217.17
	(d) Current tax assets (net)	23.85	-	24.05	0.09
	Total current assets	**1,556.17**	**1,668.67**	**1,716.73**	**1,796.26**
	Assets of disposal group classified as held for sale	-	-	24.09	31.70
	TOTAL - ASSETS	**5,195.68**	**5,113.20**	**5,680.18**	**5,729.64**
B	**EQUITY AND LIABILITIES**				
1	**Equity**				
	(a) Equity share capital	38.26	38.26	38.26	38.26
	(b) Other equity	4,471.21	4,441.85	3,873.94	3,873.03
	Equity attributable to owners	**4,509.47**	**4,480.11**	**3,912.20**	**3,911.29**
	Non-controlling interest	-	-	74.66	122.54
	Total equity	**4,509.47**	**4,480.11**	**3,986.86**	**4,033.83**
2	**LIABILITIES**				
	(a) Financial liabilities				
	I. Borrowings	28.10	50.48	28.10	50.48
	II. Lease liabilities	33.51	39.22	195.85	205.57
	III. Other financial liabilities	-	-	503.74	695.53
	(b) Provisions	-	-	0.40	0.40
	(c) Deferred tax liabilities,(net)	42.31	38.68	99.84	97.90
	Total non-current liabilities	**103.92**	**128.38**	**827.93**	**1,049.88**
	Current liabilities				
	(a) Financial liabilities				
	I. Borrowings	95.76	44.76	199.60	119.19
	II. Lease liabilities	11.17	11.17	24.86	25.25
	III. Trade payables				
	a) Total outstanding dues of micro enterprises and small enterprises	29.95	44.82	30.09	45.33
	b) Total outstanding dues of creditors other than micro enterprises and small enterprises	298.50	215.33	334.23	239.25
	IV. Other financial liabilities	35.25	79.36	144.67	93.75
	(b) Other current liabilities	47.57	48.16	64.29	59.43
	(c) Provisions	47.27	44.75	50.51	47.29
	(d) Current tax liabilities,(net)	16.82	16.36	17.14	16.44
		582.29	**504.71**	**865.39**	**645.93**
	Total liabilities	**686.21**	**633.09**	**1,693.32**	**1,695.81**
	TOTAL - EQUITY AND LIABILITIES	**5,195.68**	**5,113.20**	**5,680.18**	**5,729.64**

WALKER CHANDIOK & Co LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited)

COHANCE LIFESCIENCES LIMITED

(formerly known as Suven Pharmaceuticals Limited)

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Disclosure of Standalone Statement of Cash Flows as per Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30 September 2026

Rs. in Crores

Particulars		For period ended 30-Sep-2026 Unaudited	For period ended 30-Sep-2025 Unaudited
A. Cash flow from operating activities			
Profit before tax		1.95	191.76
Adjustments :			
Depreciation and amortisation expense (including exceptional item)		68.44	64.57
Finance costs		4.97	10.64
Share based payment expense		6.00	5.97
Other Balances written off		12.20	-
Loans and advances written off		7.00	-
Loss/(Profit) on disposal of property, plant and equipment (net)		2.87	(6.56)
Fair value loss/(gain) on financial instruments,(net)		(14.89)	-
Derivative impact on forward liability		(8.41)	(10.83)
Expected credit loss on financial asset		(0.64)	2.82
Net gain on current investment carried at fair value through profit or loss		(11.58)	(10.87)
Unrealised foreign exchange fluctuations,(net)		(6.03)	(6.93)
Interest income		(0.43)	(1.16)
Insurance claim received		(1.00)	-
Loss/(Gain) on lease modifications		(0.58)	0.18
Balances no longer required written back		-	(0.06)
Operating profit before working capital changes		59.87	239.53
Adjustments for working capital			
Increase in inventories		(168.83)	(124.02)
Decrease in trade receivables and other receivables		231.52	225.87
Increase/(Decrease) in trade payables and other liabilities		58.10	(5.44)
Cash generated from operations		180.66	335.94
Income taxes paid (net of refunds)		21.12	(57.99)
Net cash flows generated from operating activities	**(A)**	201.78	277.95
B. Cash flow from investing activities			
Purchase of property, plant and equipment (refer note (ii))		(78.13)	(66.56)
Proceeds from Insurance claims		4.00	-
Proceed from sale of current investments		439.63	162.66
Purchase of current investments		(332.46)	(258.50)
Investment in subsidiary		(249.14)	-
Investment in non-current financial asset		(0.23)	(1.50)
Interest received		0.51	0.53
(Investment)/Proceeds in other bank balance and cash not available for immediate use		0.27	(8.97)
Net cash flow used in investing activities	**(B)**	(215.55)	(172.34)
C. Cash flows from financing activities			
Proceeds from/(Repayment) of short-term borrowings (net)		51.00	(14.97)
Repayment of long-term borrowings		(22.38)	(50.65)
Payment of stamp duty on account of merger		-	(50.00)
Proceeds from issue of equity shares		1.10	32.43
Repayment of lease liabilities - Principal		(4.70)	(5.34)
Repayment of lease liabilities - Interest		(2.17)	(2.67)
Finance costs paid		(2.85)	(7.94)
Net cash flow used in financing activities	**(C)**	20.00	(99.14)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	6.23	6.47
Cash and cash equivalents as at the beginning of the period		13.11	30.61
Effect of exchange differences on cash and cash equivalents		-	(0.11)
Cash and cash equivalents at the end of the period (refer note iii)		19.34	36.97

Components of Cash and cash equivalents	30 September 2026	30 September 2025
Balance with banks:		
in current accounts	17.96	21.87
in EEFC account	0.29	2.62
in cash credit accounts	1.13	12.46
Cash on hand	(0.04)	0.02
	19.34	36.97

Notes:

i. The above statement of cashflow has been prepared under the 'Indirect Method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows.

ii. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment, investment properties and right of use of assets adjusted for movement of capital work-in-progress, capital advances, capital creditors during the year.

iii. Component of cash and cash equivalent includes cash in hand and bank balance in current account, EEFC accounts and cash credit accounts and fixed deposits with original maturity of less than 3 months.

WALKER CHANDIOK & Co LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals Limited) ★

COHANCE LIFESCIENCES LIMITED

(formerly known as Suven Pharmaceuticals Limited)

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Disclosure of Consolidated Statement of Cash Flows as per Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30 September 2026

Rs. in Crores

Particulars	For period ended 30-Sep-2026 Unaudited	For period ended 30-Sep-2025 Unaudited
A. Cash flow from operating activities		
Profit before tax	**(53.62)**	**146.53**
Adjustments :		
Depreciation and amortisation expense (including exceptional item)	99.71	91.17
Finance costs	14.33	17.42
Share based payment expense	7.96	5.97
Other Balances written off	12.20	-
Loans and advances written off	7.00	-
Loss/(Profit) on disposal of property, plant and equipment (net)	2.80	(6.56)
Fair value loss/(gain) on financial instruments,(net)	(14.89)	-
Expected credit loss on financial asset	(14.45)	4.62
Net gain on current investment carried at fair value through profit or loss	(12.01)	(10.93)
Unrealised foreign exchange fluctuations,(net)	(6.03)	(7.42)
Non - cash transactions	(1.50)	-
Interest income	(0.72)	(1.50)
Insurance claim received	(1.00)	-
Loss/(Gain) on lease modifications	(0.58)	0.18
Balances no longer required written back	-	(0.06)
Operating profit before working capital changes	**39.20**	**239.42**
Adjustments for working capital		
Increase in inventories	(172.03)	(125.51)
Decrease in trade receivables and other receivables	230.59	205.58
Increase in trade payables and other liabilities	73.55	2.92
Cash generated from operations	**171.31**	**322.41**
Income taxes paid (net of refunds)	16.75	(61.27)
Net cash flows generated from operating activities (A)	**188.06**	**261.14**
B. Cash flow from investing activities		
Purchase of property, plant and equipment (refer note (ii))	(108.01)	(89.71)
Proceeds from sale of property, plant and equipment	7.61	-
Proceeds from insurance claims	4.00	-
Proceed from sale of current investments	441.67	162.84
Purchase of current investments	(348.46)	(263.30)
Investment in subsidiaries net of cash and cash equivalents acquired	(44.96)	-
Investment in non-current financial asset	(0.23)	(1.50)
Interest received	0.91	1.61
(Investment)/Proceeds in other bank balance and cash not available for immediate use	0.78	(4.06)
Net cash flow used in investing activities (B)	**(46.69)**	**(194.12)**
C. Cash flows from financing activities		
Proceeds from/(repayment of) short-term borrowings (net)	79.13	31.89
Repayment of long-term borrowings	(22.38)	(69.68)
Payment of Stamp duty on account of merger	-	(50.00)
Acquisition of additional interest in subsidiary	(124.40)	-
Proceeds from issue of equity shares	1.10	32.43
Repayment of lease liabilities - Principal	(11.54)	(10.10)
Repayment of lease liabilities - Interest	(8.64)	(9.01)
Finance costs paid	(5.74)	(8.38)
Net cash flow used in financing activities (C)	**(92.47)**	**(82.85)**
Net decrease in cash and cash equivalents (A+B+C)	48.90	(15.83)
Cash and cash equivalents as at the beginning of the period	49.14	96.65
Effect of exchange differences on cash and cash equivalents	0.59	1.75
Cash and cash equivalents at the end of the period	**98.63**	**82.57**

Components of Cash and cash equivalents	30 September 2026	30 September 2025
Balance with banks:		
in current accounts	93.56	67.41
in EEFC account	3.93	2.65
in cash credit accounts	1.13	12.46
Cash on hand	0.01	0.05
	98.63	**82.57**

Notes:

i. The above statement of cashflow has been prepared under the 'Indirect Method' as set out in Indian Accounting Standard (Ind AS) 7-Statement of Cash Flows.

ii. Purchase and sale of property, plant and equipment represents additions and deletions to property, plant and equipment, investment properties and right of use of assets adjusted for movement of capital work-in-progress, capital advances, capital creditors during the period.

iii. Component of cash and cash equivalent includes cash in hand and bank balance in current account, EEFC accounts and cash credit accounts and fixed deposits with original maturity of less than 3 months.

WALKER CHANDIOK & Co LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited (Formerly Suven Pharmaceuticals Limited)

Notes

1) The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 6 November 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified conclusion.

2) The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3) The Company reportable activity falls under single operating segment i.e. Contract Development and Manufacturing Operations (CDMO), hence segment reporting as per Ind AS 108 (Operating Segment) is not presented.

4) The exceptional item for the previous period / year includes
a) One -time restructuring expenses of ₹8.10 crores incurred pursuant to the merger of the Company with its erstwhile fellow subsidiary, Cohance Lifesciences Limited for the six month period ended 30 September 2025 and year ended 31 March 2026.
b) Claim payable to a customer pursuant to a one-time settlement agreement amounting to ₹16.51 crores for the year ended 31 March 2026.
c) Impact of implementation of new labour code for ₹4.86 crores for the year ended 31 March 2026.

5) Pursuant to definitive agreements dated 2 September 2026, the Company acquired an additional 65% shareholding in Aaruka Bio Inc. ("Aaruka") for a consideration of ₹47.89 crore, thereby increasing its aggregate shareholding to 90%. The conditions precedent under the agreements were fulfilled on 19 September 2026 and, consequently, the Company obtained control over Aaruka on that date, resulting in Aaruka becoming a subsidiary of the Company.

Based on its assessment under Ind AS 103, "Business Combinations", the Company concluded that Aaruka does not meet the definition of a business and, accordingly, accounted for the transaction as an asset acquisition. The consolidated financial results for the quarter and six months ended 30 September 2026 include the impact of the above transaction with effect from 19 September 2026.

6) Pursuant to the Share Purchase Agreement entered into between the Company and NJ Bio Inc., the Company acquired an additional 11.3% equity interest in NJ Bio Inc. for a consideration of ₹124.40 crore, thereby increasing its shareholding in NJ Bio Inc. to 67.3%. Consequently, the Company derecognised the put option liability and the non-controlling interest (NCI) relating to NJ Bio Inc. The resulting difference has been recognised directly in other equity, as the transaction represents a change in the Company's ownership interest in a subsidiary without a loss of control.
Further, the Company subscribed to 188.680 compulsorily convertible preference shares (CCPS) of NJ Bio Inc. for a consideration of ₹95.56 crore, which are contractually required to be converted into equity shares at the end of the specified period.

7) In July 2026, the Nomination and Remuneration Committee of the Company modified the terms and conditions of the existing ESOP 2023 Plan and granted new ESOP under ESOP 2023 and ESOP 2026 Plan.
The Company has accounted for the impact of the modification and the grant during the period.

8) Subsequent to the period end, the CCPS of Sapala Organics Private Limited ("Sapala") were converted into equity shares of Sapala in a 1:1 ratio, resulting in a reduction in the Company's shareholding in Sapala from 67.5% to 51%. However, Sapala continues to be a subsidiary, as the dilution in the Company's shareholding does not result in a loss of control. In accordance with the terms of the revised Agreement, the Company is required to acquire an additional 21% shareholding in Sapala based on FY'27 performance and the remaining 28% by 31 March 2030.

9) Subsequent to the period end, an industrial accident occurred during the manufacturing process at the Suryapet facility of the Company, resulting in an unfortunate fatality, the Telangana Pollution Control Board ("TGPCB") issued an order dated 5 November 2026 directing the closure of operations at the facility. Management is undertaking necessary measures in response to the order.

For and on behalf of the Board
Cohance Lifesciences Limited
(formerly known as Suven Pharmaceuticals Limited)

Umang Vohra
Chairman and Group CEO
DIN: 02296740

Place : Mumbai
Date : 6 November 2026

WALKER CHANDIOK & Co LLP ★ CHARTERED ACCOUNTANTS ★

Cohance Lifesciences Limited ★ (Formerly Suven Pharmaceuticals Limited) ★

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

L-41, Connaught Circus,
Outer Circle,
New Delhi - 110 001
India

T +91 11 4500 2219
F +91 11 4278 7071

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cohance Lifesciences Limited (formerly known as Suven Pharmaceuticals Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Cohance Lifesciences Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Ashish Gupta
Digitally signed by Ashish Gupta
Date: 2026.11.06 15:59:19 +05'30'

Ashish Gupta
Partner
Membership No.: 504662

UDIN: 26504662XYYWZK6754

Place: New Delhi
Date: 6 November 2026

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

L-41, Connaught Circus,
Outer Circle,
New Delhi - 110 001
India

T +91 11 4500 2219
F +91 11 4278 7071

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Cohance Lifesciences Limited (formerly known as Suven Pharmaceuticals Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Cohance Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries, included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 1 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of one subsidiary included in the Statement, whose financial information reflects total assets of ₹21.51 crore as at 30 September 2026, and total revenues of ₹3.39 crore and ₹6.83 crore, total net profit after tax of ₹0.42 crore and ₹1.12 crores, total comprehensive income of ₹0.42 crore and ₹1.11 crore, for the quarter and year-to-date period ended on 30 September 2026, respectively, and net cash outflows of ₹7.45 crores for the period ended 30 September 2026, as considered in the Statement. These interim financial results have been reviewed by other auditors whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Ashish Gupta

Digitally signed by Ashish Gupta
Date: 2026.11.06 16:00:49 +05'30'

Ashish Gupta
Partner
Membership No. 504662

UDIN: 26504662IJNZTC6411

Place: New Delhi
Date: 06 November 2026

Annexure 1

List of entities included in the Statement

Subsidiaries

1. Sapala Organics Private Limited, India
2. Cohance Lifesciences Inc, USA
3. NJ Bio Inc, USA
4. NJ Bio India Pharmaceuticals Private Limited, India
5. NJ Biotherapeutics LLC, USA (Upto 18 September 2026)
6. Aruka Bio Inc, USA (Associate Upto 18 September 2026)

Cohance Lifesciences Announces Q2 & H1FY27 Results

Q2 delivered sequential growth; H2 to drive YoY growth in revenue and EBITDA

Hyderabad/Mumbai, 6 November 2026

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited), a leading global contract development and manufacturing organisation (CDMO), today announced its unaudited financial results for the second quarter and half year ended 30 September 2026.

Q2FY27 Financial Performance

- Q2 FY27 revenue from operations was ₹4,767 million, increasing 12.9% sequentially and declining 14.2% year-on-year. Gross margin was 70.8%, compared with 74.6% in Q2 FY26, reflecting an unfavourable business and product mix. Adjusted EBITDA was ₹458 million, with an adjusted EBITDA margin of 10%, compared with 2.2% in Q1 FY27.

H1FY27 Financial Performance

- H1 FY27 revenue from operations was ₹8,989 million, down 18.6% year-on-year. Gross margin was 71.1%, compared with 73.8% in H1 FY26. Adjusted EBITDA was ₹551 million, with an adjusted EBITDA margin of 6.1%.

Mr. Umang Vohra, Executive Chairman and Group CEO, said: *"Q2 reflects an improving business trajectory and the broader Cohance platform beginning to come together. We expect H2 to be materially stronger than H1, with year-on-year growth in both revenue and EBITDA, supported by improving visibility across our businesses. At the same time, we remain focused on progressing our regulatory commitments and maintaining the highest standards of quality and compliance across our facilities. We see significant value potential as we continue to integrate and scale the Cohance platform, and we are still at the beginning of that journey"*

Key Business Highlights of H1FY27

- Small Molecules: Stronger Q3/Q4 order visibility and multiple commercial reload orders received, supporting improved delivery schedules and H2 recovery
- Secured three significant programmes with large global pharma customers, comprising two commercial and one Phase III programme
- Two molecules moved into commercial supply, with two additional molecules expected over the next 12–15 months, including one with US FDA approval
- NJ Bio successfully delivered two ADC GMP campaigns, including an end-to-end development programme. One customised payload programme is progressing through scale-up
- Nucleic Acid business is seeing strong demand for specialised nucleosides and amidites, with increasing commercial opportunities and larger-scale manufacturing programmes across the Cohance network
- Qualification programmes progressing with two Japanese customers, alongside opportunities with a European innovator and potential manufacturing transfers
- NJ Bio, Inc. was named Runner-Up in the Best Contract Research Organization (CRO) category at the 2026 World ADC Awards, marking seven consecutive years of recognition at the event

Outlook

H2 FY27 is expected to be materially stronger than H1 FY27, supported by Small Molecule deliveries and reloads, continued resilience in API+, nucleic-acid growth and progressive improvement across the portfolio. Higher revenue conversion, improved utilisation and a better business mix are expected to support progressive margin recovery. The strategic direction remains unchanged.

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Through its integrated platform and facilities in India and the US, Cohance provides solutions from early development through commercial supply for leading global pharmaceutical companies.

For more information, please contact: www.cohance.com

Cyndrella Carvalho, Head - Investor Relations,
Cohance Lifesciences Limited
Tel: 040 2354 3311
Email: cyndrella.carvalho@cohance.com

Gavin Desa / Konpal Pali
CDR India
Tel: +91 98206 37649 / 76619 08341
Email: gavin@cdr-india.com; konpal@cdr-india.com

INVESTOR PRESENTATION

Q2 FY2027

November 2026



Cohance

Disclaimer

This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to media or reproduced in any form, without prior written consent Cohance Lifesciences


This document is based on information obtained from public sources and sources believed to be reliable and information contained in this presentation concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates

Under no circumstances shall Cohance Lifesciences or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the content or any use thereof





Table of Contents



Executive summary 04

Business and Financial performance 06

Awards & Recognition and ESG 15

Business wise Strategy 19

Annexure 30

Cohance

Executive Summary



Executive Summary – Q2FY27 and H1FY27

Q2FY27: Sequential recovery gaining traction; integrated capabilities strengthening the growth platform

- **Q2 delivered a clear sequential recovery**, with revenue up ~13% QoQ and adjusted EBITDA margin improving to 10% from 2% in Q1, demonstrating progress from the Q1
- **Strategic Progress: One Cohance integration** is driving operational and commercial progress across businesses
  - **Pharma CDMO:**
    - In Small Molecules, the order and reload position for Q3 and Q4 has improved materially. Secured two new commercial and one late-stage programme with large global pharma customers, strengthening relationships and medium-term growth opportunities
    - In nucleic acid business, Sapala's strong performance is supported by increasing integration of its specialised chemistry and customer relationships with Cohance's development and manufacturing network.
  - **API+:** API+ revenue grew YoY, supported by selective pricing actions, while lower API volumes, shipment phasing and higher raw-material costs impacted margins.
  - **Specialty Chemicals:** Specialty Chemicals declined YoY due to lower AgChem volumes, pricing pressure and programme phasing, while Performance Materials remained relatively stable.
- Focused on expanding customer value-chain participation and improving programme conversion through integrated development-to-manufacturing capabilities, including bioconjugation, ADC payload-linkers and R&D infrastructure.
- Will maintain disciplined capital allocation, with investments phased based on customer visibility, project readiness and expected returns.

FY27 Outlook: Stronger H2 expected

- H2FY27 revenue and EBITDA expected to grow YoY, supported by continued recovery and progressive integration of Cohance's capabilities to unlock platform potential. H2 focus is on improving revenue mix and utilisation to support progressive margin recovery.
- H2 is expected to be stronger than H1, driven by Small Molecule deliveries, API+ resilience and Sapala growth, with improved revenue mix and utilisation supporting EBITDA recovery.

Proposed Capex

- Company plans to announce capex investment towards building capabilities in adjacencies and R&D to unlock the full potential of the One Cohance platform.

Cohance

Business and Financial Performance



Q2FY27: Q2 Delivered Sequential Growth

Q2FY27 performance:

- Q2FY27 revenue declined 14.2% YoY to INR 4,766 Mn, due to lower Pharma CDMO and AgChem contributions and an unfavourable business and product mix. Q2 delivered 12.9% sequential revenue growth and EBITDA margins of 9.6%
- Pharma CDMO down 27.4% YoY in Q2 and 32.7% in H1; sequential recovery expected to continue in H2
- Our Niche technology share contributed 13.7% of revenues
- API+ segment grew 6.2% YoY, thus continuing to provide resilience. API+ revenue grew YoY, supported by selective pricing actions, while lower API volumes, shipment phasing and higher raw-material costs impacted margins
- Nucleic Acid business (Sapala) grew 33.6% YoY in Q2 driven by strong demand for specialised nucleic-acid building blocks, with no early Phase III supplies contribution
- Specialty Chemicals revenue declined by 40.6% YoY, due to lower AgChem volumes, pricing pressure and programme phasing, while Performance Materials remained relatively stable.
- Gross margins contracted to 70.8%, down 377 basis points YoY. Margins impacted by unfavourable product mix, lower AgChem contribution, weaker Small Molecule revenue conversion and API+ raw-material inflation, partly offset by Sapala and Formulations
- Adjusted EBITDA for Q2 FY27 was INR 459 Mn, with margins at 10%.
- Adjusted PAT also returned to positive territory during the quarter.


Healthy cash generation in H1FY27

- Free cash flow of INR 1,338 Mn generated during the quarter. Cash on books stood at INR 2,943 Mn, maintaining a healthy liquidity position
- INR 1,077 Mn capex deployed in H1, as we continued investing in capabilities required for future growth

Q2FY27 Financial Highlights

12.9% Revenue growth QoQ)	**6.2%** API+ growth (YoY)	**33.6%** Sapala revenue growth (YoY)
INR 4.77 Bn Total Revenue	**INR 459 Mn*** Adjusted EBITDA	**INR 74 Mn*** Adjusted Profit/(loss) after Tax
70.8% Gross Margins	**9.6%** EBITDA% excl. one time	**13.7%** Niche Tech as % of revenue

Q2FY27 Segmental Revenue (YoY) – CDMO# share at 44%



Note:

1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 68 Mn in Q2FY27 Vs INR 55 Mn in Q2FY26
2) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

#CDMO includes Pharma CDMO and Specialty Chemicals

Q2FY27 Consolidated Financial Results

INR Mn

Particulars	Q2FY27	Q1FY27	Q2FY26	QoQ	YoY
Revenue from Operations	**4,766**	**4,223**	**5,556**	**12.9%**	***-14.2%***
Material costs / COGS	(1,391)	(1,203)	(1,412)		
Material Margin	**3,375**	**3,020**	**4,144**	**11.8%**	***-18.6%***
Material Margin %	*70.8%*	*71.5%*	*74.6%*		
Manufacturing Expenses	(1,059)	(934)	(1,019)		
Employee Cost	(1,533)	(1,331)	(1,267)		
Other Expenses	(428)	(743)	(631)		
Total Expenses	(3,020)	(3,008)	(2,918)		
EBITDA (Reported)	**355**	**12**	**1,226**	**2858.3%**	***-71.1%***
EBITDA (Reported) %	*7.4%*	*0.3%*	*22.1%*		
FX MTM gain	36	54	7		
One-time expenses	68	26	55		
EBITDA (Adjusted)	**459**	**92**	**1,288**	**398.9%**	***-64.4%***
EBITDA (Adjusted) %	*9.6%*	*2.2%*	*23.2%*		
Depreciation & Amortization	(504)	(494)	(441)		
Finance costs	(83)	(68)	(87)		
Other income	89	68	130		
Profit/(loss) Before Tax (Adjusted)	**(40)**	**(401)**	**890**		
Exceptional Items	0	0	0		
Adjusted Profit/(loss) before tax	**(40)**	**(401)**	**890**		
Tax(Adjusted)	114	(28)	(182)		
Profit/(loss) After Tax (Adjusted)	**74**	**(429)**	**709**		
PAT Margin %	*1.6%*	*-10.2%*	*12.8%*		
Profit/(loss) After Tax (Reported)	**152**	**(240)**	**739**		
PAT Margin %	*3.2%*	*-5.7%*	*13.3%*		

- In Q2, CDMO (Pharma CDMO + Specialty Chemicals) share was 44%, only API+ business saw growth. Niche tech contribution stood at 13.7%
- Gross margins contracted by 377 bps YoY due to an unfavourable product mix, lower AgChem contribution, weaker Small Molecule revenue conversion and API+ raw-material inflation, partly offset by Sapala and Formulations
- Adjusted EBITDA margin improved to 10% from 2% in Q1

Note:

1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 68 Mn in Q2 FY27 Vs INR 55 Mn in Q2 FY26 and INR 94 Mn in H1 FY27 Vs INR 225 Mn in H1 FY26
2) Exceptional item for H1FY26 INR 81 Mn represents one-time restructuring costs incurred due to merger of the Company with erstwhile Cohance Lifesciences Limited
3) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)
4) PAT (Reported) is after considering Profit /(Loss) attributable to NCI for Sapala& NJ Bio is of (INR 130 Mn) in Q2FY27 Vs (INR 77 Mn) in Q2FY26 and INR 341 Mn in H1 FY27 Vs INR 101 Mn in H1 FY26
5) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

H1FY27 Consolidated Financial Results

INR Mn

Particulars	1HFY27	1HFY26	YoY
Revenue from Operations	**8,989**	**11,049**	***-18.6%***
Material costs / COGS	(2,594)	(2,893)	
Material Margin	**6,395**	**8,156**	***-21.6%***
Material Margin %	*71.1%*	*73.8%*	
Manufacturing Expenses	(1,993)	(1,975)	
Employee Cost	(2,864)	(2,600)	
Other Expenses	(1,171)	(1,233)	
Total Expenses	(6,028)	(5,808)	
EBITDA (Reported)	**367**	**2,348**	***-84.4%***
EBITDA (Reported) %	*4.1%*	*21.3%*	
FX MTM gain	90	56	
Onetime expenses	94	225	
EBITDA (Adjusted)	**551**	**2,629**	***-79.0%***
EBITDA (Adjusted) %	*6.1%*	*23.8%*	
Depreciation & Amortization	(998)	(891)	
Finance costs	(151)	(189)	
Other income	157	222	
Profit/(loss) Before Tax (Adjusted)	**(441)**	**1,771**	***-124.9%***
Exceptional Items	0	(81)	
Adjusted Profit/(loss) before tax	**(441)**	**1,690**	
Tax(Adjusted)	86	(389)	
Profit/(loss) After Tax (Adjusted)	**(355)**	**1,301**	***-127.3%***
PAT Margin %	*-3.9%*	*11.8%*	
Profit/(loss) After Tax (Reported)	**(88)**	**1,228**	
PAT Margin %	*-1.0%*	*11.1%*	

- In H1FY27, CDMO (Pharma CDMO + Specialty Chemicals) share was 41%, all the business segments witnessed revenue decline. Niche tech contribution stood at 14.4%
- Nucleic acid (Sapala) revenue grew by ~83% YoY in H1
- H2 FY27 consolidated performance is expected to be stronger than H1

INR Mn

Balance Sheet Highlights	
As on 30th September 2026	
Shareholders' funds	**39,122**
Non-Controlling Interests	**747**
Net Fixed assets	36,394
Other net assets[1]	2,809
Net cash/(debt)[2]	666
Total Use of Funds	**39,869**


1) Other assets calculated as Inventories + Trade receivables + Non-current investments + Current tax assets + Other assets less Trade payables + deferred tax liabilities + Other liabilities +Forward liability at the end of the period . 2) Net cash/(debt) calculated as the cash & cash equivalents (cash and bank balances + current Investments) less Total debt (Short-term and Long-term borrowings) at the end of the period.


Note:


1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 68 Mn in Q2 FY27 Vs INR 55 Mn in Q2 FY26 and INR 94 Mn in H1 FY27 Vs INR 225 Mn in H1 FY26
2) Exceptional item for H1FY26 INR 81 Mn represents one-time restructuring costs incurred due to merger of the Company with erstwhile Cohance Lifesciences Limited
3) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)
4) PAT (Reported) is after considering Profit /(Loss) attributable to NCI for Sapala& NJ Bio is of (INR 130 Mn) in Q2FY27 Vs (INR 77 Mn) in Q2FY26 and INR 341 Mn in H1 FY27 Vs INR 101 Mn in H1 FY26
5) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)


Q2FY27 –Business Performance Overview


Consolidated Financials















Due to the lumpy nature of the CDMO Industry, Quarterly comparisons are not reflective of consistent performance


Note:


1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 68 Mn in Q2FY27 Vs INR 55 Mn in Q2FY26
2) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)


H1FY27 –Business Performance Overview


Consolidated Financials














Due to the lumpy nature of the CDMO Industry, Quarterly comparisons are not reflective of consistent performance

Note:

1) Adjusted EBITDA is after One-time adjustment for ESOP, Merger and acquisition costs of INR 94 Mn in H1 FY27 Vs INR 225 Mn in H1 FY26
2) Adjusted PAT is after One-time adjustment for ESOP, Merger and acquisition costs (Net of tax)

Balance Sheet H1FY27

INR Mn

Balance Sheet Snapshot[1]	FY25	FY26	1HFY27
Property, plant and equipment (PPE)	15,583	17,907	17,511
Right of use asset (RoU)	2,418	2,311	2,161
Capital work-in-progress	3,316	1,732	2,158
Intangible Assets	13,453	13,832	14,563
Fixed Assets	**34,770**	**35,782**	**36,394**
Inventories	4,674	5,622	7,343
Trade receivables	7,721	6,810	4,690
Trade payables	(2,685)	(2,845)	(3,643)
Core Net Working Capital (Core NWC)	**9,710**	**9,587**	**8,390**
Other net assets	(432)	397	385
Forward liability	(6,519)	(6,955)	(5,967)
Borrowings	(2,583)	(1,697)	(2,277)
Cash and Cash equivalents (including liquid investments)	2,983	3,224	2,943
Net (debt) / cash	**400**	**1,527**	**666**
Net assets	**37,929**	**40,338**	**39,869**
Shareholder's funds	**36,488**	**39,113**	**39,122**
Non Controlling interests	**1,441**	**1,225**	**747**

- The balance sheet remains resilient and net cash positive as on 30 September 2026, despite integration and capacity expansion across key growth platforms including previous acquisitions
- Free cash flow of INR 1,338 Mn generated during the quarter. Cash on books stood at INR 2,943 Mn, maintaining a healthy liquidity position
- Gross borrowings increased to INR 2,277 Mn, however, healthy liquidity and financial flexibility was maintained. Balance sheet remained steady, with total shareholders' funds at INR 39,122 Mn and net cash position of INR 666 Mn as on 30 September 2026
- The Company continues to maintain a disciplined capital allocation approach, supported by strong internal accruals and a steady balance sheet position

Note:

1) FY24 Numbers are Proforma numbers for merged entity
2) FY25 consolidated figures are restated pursuant to Merger
3) PPE includes assets held for sale -As per SPA of Sapala INR 244 Mn as on H1FY27

Financial Ratios 1HFY27

Key Ratios(Adjusted)#	FY25	FY26	1HFY27	Basis
Net Working Capital (as days of sales)	136	154	148	NWC / Revenue * 365 days
PPE (as % of sales)	57.2%	81.7%	81.9%	PPE / Revenue
Capex spend during the year/period (INR Mn)	3,147	2,154	1,077	
Capex spend (as % of sales)	12.1%	9.5%	12.0%	Capex spend / Revenue
(Net Debt)/ Net Cash to adjusted EBITDA (x times)	0.05x	0.32x	0.25x	Net Debt / Adjusted EBITDA
ROCE (%)	26.9%	10.8%	3.2%	Adjusted EBIT / Avg. Capital employed
ROE (%)	19.1%	7.0%	1.2%	Adjusted PAT / Avg Shareholder's funds

Note:

1) FY24 Numbers are Proforma numbers for merged entity
2) The above ratios for FY25,FY26 & H1FY27 are after considering Sapala and NJ Bio consolidation
3) Key ratios (Adjusted) are computed on LTM basis considering Net fixed assets, Other net assets and shareholders funds excluding goodwill and fair value changes in assets & liabilities on account of mergers/acquisitions

Cohance

Awards & Recognition and ESG



Awards

Recognition for excellence in ADC CRO services



NJ Bio, Inc. was named Runner-Up in the Best Contract Research Organization (CRO) category at the 2026 World ADC Awards, marking seven consecutive years of recognition

Cohance

Achievements

Independent recognition of Cohance's safety culture and sustainability performance

GOLD | Top 5% ecovadis Sustainability Rating JAN 2026

CDP Discloser 2025

EcoVadis Gold Rating and CDP rating

Cohance's sustainability assessment score progressed from Silver to Gold, reflecting the strength of our environmental, social and governance performance.

CDP: B rating (Climate Change
A- rating (Water Security)

NEXT: RETAIN GOLD RATING AND CDP MANAGEMENT LEVEL FOR 2027

BRITISH SAFETY COUNCIL



British Safety Council International Safety Award 2026 (Merit)

Awarded to our two API sites and two CDMO sites, recognising excellence in health, safety and wellbeing management

NEXT: FIVE-STAR CERTIFICATION & SWORD OF HONOUR FOR 2027

Science-Based Targets: SBTi Validation

Near-term and net-zero emissions targets formally validated by SBTi Services

SCIENCE BASED TARGETS
DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

SBTi Services has validated that Cohance Lifesciences' greenhouse gas emissions reduction targets conform with the SBTi Criteria and Recommendations (Near-Term Criteria V5.3 and Net-Zero Criteria V1.3).


APPROVED 24 JULY 2026

NET-ZERO

By FY2050


Net-zero greenhouse gas emissions committed across the full value chain

NEAR-TERM — FY2035



Absolute reduction from a FY2025 base year. Scope 3 emissions reduced 35.0% within the same timeframe

LONG-TERM — FY2050



Absolute reduction from a FY2025 base year. Scope 3 emissions reduced 90.0% within the same timeframe

ESG Aspirations

We have set multi-dimensional ESG goals

Our achievement

- Achieved **B** rating in Climate Change and A- Water in 2025
- **Gold** in EcoVadis Sustainability assessment for Cohance.
- Installation of 7 MWp solar power plant under Group Captive (GC) model is completed for Ankleswar site.
- *Targets have been **approved** by SBTi for Combine entity
- Pharmaceutical Supply Chain Initiative (PSCI) **Supplier Partner** – 2025
- UNGC - Yearly CEO commitments given to implement universal sustainability principles
- **97%** score in TFS audit
- British Safety Council's International Safety Awards (ISA) 2026. (Merit)
- All facilities are certified with ISO 14001, ISO 45001, ISO 37001, ISO 27001, ISO 20400, ISO 50001, ISO 22307. ISO 9001.

Environment

58+%	Reduce absolute Scope 1,2 emissions from current level (2035)
35+%	Reduce absolute Scope 3 emissions from current level (2035)
90+%	Transition to renewable energy sources of total energy use and Reduce absolute Scope 1,2 and 3 emissions from current level (2050)
30%	Reduce, reuse and recycle specific water consumption by 2030
15%	Reduction in hazardous waste going to landfill by 15% by 2030

Social

100%	Employees undergo Health and Safety training
20+%	Representation of Women workforce by 2030
<10%	Reduce Attrition by FY28
CSR	Promote public health education and disease prevention
Zero	Reportable Loss time injury

Governance

ZERO	Ethical non-compliance
ZERO	Regulatory non-compliance or fines
100%	Employees and Board Members to acknowledge the Code Of Conduct

Upcoming milestones

- Retention of Eco Vadis Gold in Sustainability assessment
- Signing third party purchase agreement for renewable power for all the facilities
- British safety council **five-star** certification and sword of honor-2026
- ISO 28000 certification U/P
- SA 8000 recertifications for all sites

ESG Profile

ESG WORLD

***Baseline Year FY 2024-25**

Combined SBTi targets are approved on 24th July 2026

Near-Term: Cohance Lifesciences aims to cut Scope 1 & 2 GHG emissions by **58.8%** and Scope 3 emissions by **35.0%** by **FY2035** from a FY2025 baseline.

Long-Term: Cohance Lifesciences targets a **90.0% reduction** in Scope 1, 2, and 3 GHG emissions by **FY2050** compared to FY2025 levels.

Cohance

Sustainability Progress

Completed projects, assessments and management systems

Environmental projects

7 MWp	ANK: SURJA-II solar plant Group captive model 10.85m kWh/year renewable power ~7,714 tCO_2e GHG reduction[1]
Boiler conversion	ACP: briquette-fired boiler Replaced diesel-fired thermic fluid heater ~3,626 tCO_2e GHG reduction[1]
60 kL/day	NCRM: zero liquid discharge system Including boiler Installation completed
3.3 MWp	On-site solar installation completed Across CDMO Units I, III and V, and FDF IV

External assessments & disclosures

Crisil – a company of S&P Global
61 - Overall ESG
67 - Core ESG

S&P Global
54 - ESG Score

NSE Sustainability Ratings & Analytics
65 - ESG Score

SES Stakeholders Empowerment Services (Analyze » Educate » Empower)
72.1 - ESG Score

United Nations Global Compact
Communication on Progress completed and submitted

Social & governance

ISO initiatives completed across all sites

- **ISO 45001** – Occupational health and safety
- **ISO 27001** – Information security management
- **ISO 22301** – Business continuity management
- **ISO 37001** – Anti-bribery management

[1] Indicative project GHG impacts from the internal sustainability update. SDG icons illustrate thematic alignment.

UN SDGs: www.un.org/sustainabledevelopment. The content of this publication has not been approved by the United Nations and does not reflect the views of the United Nations or its officials or Member States.

Cohance

Business Wise Strategy



Our Growth Engines – Pharma CDMO Key Driver

Pharma CDMO*

42% of Sales

Small Molecules

- **18 Commercial** Patented molecules
- **20/20 Top** innovator relations; contributing >85% revenues
- **10 molecules in Phase-3**; RFQs growing 2x

Oligonucleotides

- Amongst few CDMOs globally specialized in Oligonucleotide and mRNA building blocks including specific delivery systems and Tri-cyclo-DNA
- Focus is on operationalising cGMP facility and progressively commercialising selected product families

ADC* Payload –linker – Bioconjugation

- Building an increasingly integrated offering across payloads, linkers and bioconjugation
- **Two unique** commercial ADCs payload supplies to Large Innovators
- **Expanding payloads portfolio and Clinical Collaborations** – working with other **3** Large Pharma Innovators. Developing new customized payloads and dedicated capacities. Supplied an adjacent payload order from EU partner
- **Drug Discovery to commercial** full chain exposure added 17 new customers in CY25 in NJ Bio, including 2 large innovator pharma companies

Specialty Chemicals*

8% of Sales

- Thrust on adding anchor relationships and identifying new growth drivers
- Strategic Business Unit to focus on growth acceleration by adding new customers and new products
- Dedicated site (Vizag), Available space for future expansion
- Relationships with innovators in AgChem, Electronic Chemicals and Performance coatings
- **AgChem:** relationship strengthening with strategic partner, getting better traction in AIs RFQ
- Good progress with new AgChem partners from Japan and EU
- **Performance Chem:** Relationship with existing partners advancing to next generation products
- Continuing progress in initiating discussion with other Innovators in similar electronics application

API+*

50% of Sales

- Expanding selectively into adjacent, higher-value opportunities and innovator lifecycle-management programmes
- Focused portfolio and market leadership in low-mid volume, specialty APIs with low competitive intensity
- Augmentation of new product pipeline continuing
- Built deep cost position through backward integration
- Top 3 player in 8 out of 10 top molecules in the API portfolio
- Offering end to end vertically integrated solutions including pellets and formulations
- We have more nearly 50 product families in the APIs and formulation business has nearly 50 ANDAs as partnered and owned put together

** FY26 Numbers*



Cohance

Pharma CDMO

Medium to Long Term Strategic Approach



Our 30+ year relationships with global innovators and proven expertise in scaling up hazardous chemistry, complex chiral and multi step synthesis offer us a significant and unique advantage.

Customer Centricity and Readiness:

- Customer at the core of all initiatives — delivering reliability, speed, and quality
- Expanded technology base, both organically and inorganically, to support customer programs in complex chemistries (e.g., Flow Chemistry)
- Deepening strategic partnerships with large pharma; leveraging existing networks and the EAB to accelerate growth in the next 12–18 months
- Partnering with select biotech innovators on emerging modalities to stay ahead of technological advancements

Strengthening our tech modalities

- ADC & Oligo: Cross-sell within existing customer base and acquire new customers through niche modalities
- Expand Flow Chemistry and Peptide capabilities organically and inorganically over the next 12–24 months

Quality of RFP and conversions

- Continue to diversify the customer base from our strategic relationship to get high quality RFPs and improve conversions (specifically laterals)

Strong Process R&D capability for speed, Quality and continuous improvement


Execution & Capacity Expansion to deliver on time


- Strong Quality track record in US FDA approved sites
- Expand capacities and improve assets for our customers (eg new capacity)
- Emphasis on scheduled commercial programme deliveries, execution of the commercial restocking order, progressive normalisation in the affected operations and improving utilisation across the platform

Pharma CDMO: Advancement across programmes

Small Molecules

- **Improved H2 visibility:** Stronger Q3/Q4 order book and improved commercial reload visibility are expected to support sequential recovery in the second half
- **Strong customer engagement**:
  - Secured three significant programmes with large global pharmaceutical customers, comprising two commercial programmes and one Phase III programme
  - New programme wins are expected to deepen relationships with strategic global pharma customers and broaden medium-term growth opportunities
- **Commercial pipeline progressing**:
  - Multiple reload orders received across existing commercial programmes, providing improved visibility into scheduled Q3/Q4 deliveries
  - Strengthening late-stage and commercial RFP activity reflects improving customer engagement and supports future growth opportunities.
- **Quality:** Continued progress on quality improvement initiatives, with ongoing focus on strengthening operational and regulatory compliance.






ADC and OLIGOS: Maintain strong outlook

ADC

- Customer destocking impacted H1 performance, while improving order visibility supports H2 recovery.
- Increasing RFQ activity across payloads and linkers, supported by an improving development pipeline.
- NJ Bio reorganisation strengthens commercial focus and integration with India's payload-linker capabilities.
- NJ Bio successfully delivered two ADC GMP campaigns, including an end-to-end development programme.
- Bioconjugation capacity expansion on track for early FY28, with focus on improving utilisation and moving towards break-even.

Market to grow at **15%+ CAGR**



Source: *: Fortune business insights, Antibody drug conjugates market, updated October 12, 2026*

Oligonucleotides


- Strong demand for specialised nucleosides, amidites and nucleic-acid building blocks supports business growth.
- Q2 growth achieved without early Phase III supplies, reflecting healthy demand across newer nucleic-acid technologies.
- Repeat orders and fee-for-service work continue to support business momentum and customer engagement.

Oligonucleotide Building-Block (Amidite) Market Opportunity – Sapala

Merchant Amidite Market:	**~US$1 bn (2025) → ~US$2 bn (2030–31E)**
Therapeutic Oligo CDMO Market:	**~US$3 bn, growing at ~20% annually**
Amidites Purchased by Oligo CDMOs:	**70–80%**

Source: *AlphaSights Market Research.*

Market to grow at **23%+ CAGR**



Source: *Global market insights, Oligonucleotides Therapeutics market size and share 2026-2036 (June 2026)*

Creating One Integrated Nucleic Acid business



Strong growth

Nucleic Acid Business (Sapala) continues to deliver strong growth and profitability, with revenue increasing 33.6% YoY in Q2 and 83.1% in H1.

Manufacturing opportunities

Integration progressing through coordinated commercial activities and leveraging Cohance's manufacturing network to support larger customer programmes and scale-up.

Focus on expansion

Focus on expanding capabilities across nucleic-acid building blocks, oligonucleotides and conjugation applications to offer integrated solutions to customers.

Bringing together chemistry, development, manufacturing and commercial supply



Cohance

API+



API+: Resilient performance

API+

- API+ continued to deliver resilient YoY revenue growth, supported by a healthy order book and selective pricing actions, despite lower volumes and raw-material cost pressures
- Strategic focus remains on niche APIs, controlled substances and innovator lifecycle-management opportunities, with increasing participation across intermediates, APIs, pellets and formulation
- H2 priorities include order book conversion, new-product execution, pricing discipline and margin improvement through better product mix and cost optimisation

Formulations

- Formulations delivered strong improvement in Q2, supported by higher commercial activity and product-development programmes
- Focus remains on executing new-product opportunities, strengthening customer relationships and expanding participation across the API-to-formulations value chain
- Continued emphasis on quality, regulatory compliance and reliable supply to support sustainable growth



Cohance

Specialty Chemicals



SPEC/Ag CHEM: Tepid performance amidst pricing pressure

Specialty Chemicals — AgChem

- AgChem performance impacted by lower volumes, pricing pressure and programme phasing across the mature portfolio.
- Strategic focus on broadening the innovator-led portfolio and converting qualification programmes into commercial supply.
- Qualification programmes progressing with global innovators, including two Japanese customers, to support future commercial opportunities.
- Opportunities emerging from supply-chain diversification and potential manufacturing transfers from existing customer locations.

Specialty Chemicals Performance Chemicals

- Core photochromic portfolio remained relatively stable, despite challenging market conditions.
- Customer engagements progressing across OLED, electronic materials and semiconductor-linked chemistry applications.
- H2 focus on executing commercial programmes, advancing customer qualifications and strengthening R&D and manufacturing capabilities to support future growth.

Cohance

Annexures



R&D and Manufacturing Facilities

Cohance

Lab & Kilo scale

Pharma CDMO


Genome valley, Hyderabad



Nacharam, Hyderabad (Oligo CoE)


Princeton, New Jersey

API+


Patancheru, Hyderabad

Spec Chem


Genome valley, Hyderabad


Vizag, Andhra Pradesh


FDF


Nacharam, Hyderabad


Pashamylaram-R&D, Hyderabad

Pilot and Commercial scale (~3,000+ kL capacity)


Suryapet, Telangana


Jeedimetla, Hyderabad


Pashamylaram, Hyderabad


Vizag, Andhra Pradesh


Nacharam, Hyderabad


Atchutapuram, Andhra Pradesh


Jaggaiahpet, Andhra Pradesh



Ankleshwar, Gujarat


Jadcherla, Telangana


Vizag, Andhra Pradesh


Pashamylaram, Hyderabad


Casper Pharma, Hyderabad


Nacharam, Hyderabad

US FDA Audited site

Contact Information



Cyndrella Carvalho, Head - Investor Relations
Cohance Lifesciences Ltd

Email: cyndrella.carvalho@cohance.com

Gavin Desa, Konpal Pali
CDR - India

Tel: +91 98206 37649; +91 76619 08341
Email: gavin@cdr-india.com; konpal@cdr-india.com

Thank You



Cohance

Annexure – II

Appointment of Dr. Kuber Jagdale

1	Name of Person	Dr. Kuber Jagdale
2	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment of Dr. Kuber Jagdale as Additional Director, designated as Chief Technical Officer & Executive Director of the Company, subject to the approval of the shareholders of the Company.
3	Date of appointment /~~re-appointment / cessation~~ (as applicable) and term of appointment / ~~re-appointment~~	Effective from 7 November 2026. Term of appointment: 5 years (from 7 November 2026 till 6 November 2031).
4	Brief profile (in case of appointment)	Dr. Kuber Jagdale has over three decades of experience in the pharmaceutical industry. He has held senior leadership positions with Cipla Limited, Sekhmet Pharma Ventures, and Emcure Pharmaceuticals Limited. His areas of expertise include manufacturing operations, active pharmaceutical ingredients (API) and finished dose formulations (FDF) production, quality management, supply chain management, technology transfer, operational excellence, cost optimization, and business leadership. Dr. Jagdale holds a B.Sc. (Tech.) in Applied Drugs from the University of Mumbai and a Ph.D. in Pharmaceutical Sciences from Kennedy University, USA. Dr. Jagdale's extensive experience in pharmaceutical manufacturing and operational leadership will support Cohance Lifesciences Limited's growth and long-term value creation."
5	Disclosure of relationship between directors (in case of appointment of a director)	Dr. Kuber Jagdale is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Annexure – III

Details regarding Acquisition (including agreement to acquire)

Sl	Particulars	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	**Name of the Target**: SPV is under incorporation, hence name of the target is not applicable. The proposed SPV will operate as a Solar power plant with a contracted capacity of 5.3 MW Wind and 4.45 MWp Solar for Captive power consumption for supply of power to Cohance.
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
c.	Industry to which the entity being acquired belongs	Renewable Energy Sector
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Captive consumption of renewable power and to achieve Green Industry status and transition towards Sustainable Energy sources. This will save CO2 emissions. Apart from this there would be savings via tariff of nearly 26%. So this results in consuming green energy while saving operational expenditure.
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable
f.	Indicative time period for completion of the acquisition;	12 to 15 Months
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
h.	Cost of acquisition and/or the price at which the shares are acquired;	Rs.5.72 Cr (Approx.)
i.	Percentage of shareholding / control acquired and / or number of shares acquired	Proposed to acquire 26% equity in the SPV subject to finalization of contractual terms.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	SPV is under incorporation in India. Hence, date of Incorporation, history of last 3 years turnover etc., are not applicable.